TY - JOUR
T1 - Systematic functional validation of IKAROS variants from patients and laboratory-generated mutations
AU - Kuehn, Hye Sun
AU - Gil Silva, Agustin A.
AU - Klangkalya, Natchanun
AU - Esteve-Sole, Ana
AU - Goel, Shubham
AU - Niemela, Julie E.
AU - Stoddard, Jennifer L.
AU - Chong, Hey
AU - Williams, Kelli
AU - Ip, Winnie
AU - Framil Seoane, Mario
AU - Loganathan, Sathish Kumar
AU - Anantharachagan, Ariharan
AU - García-Soidán, Ana
AU - Shaffren, Serena
AU - Bindernagel, Constance
AU - Mendez, Philip
AU - Miller, Rahim Z.
AU - Abolhassani, Hassan
AU - Hoytema van Konijnenburg, David P.
AU - Geerlinks, Ashley V.
AU - Cabanillas, Diana
AU - Zonneveld-Huijssoon, Evelien
AU - Rutgers, Abraham
AU - Tangye, Stuart
AU - Ma, Cindy
AU - Grey, Alice
AU - O'Young, Patrick
AU - Aldave Becerra, Juan Carlos
AU - Lyons, Jonathan J.
AU - White, Andrew A.
AU - Claiborne, Michael
AU - Doroudchi, Mohammad Ali
AU - Modena, Brian D.
AU - Milner, Joshua D.
AU - Solanich, Xavier
AU - Farela Neves, João
AU - Platt, Craig D.
AU - Hammarström, Lennart
AU - Routes, John M.
AU - Verbsky, James
AU - Butte, Manish J.
AU - Lesmana, Harry
AU - Griffiths, William J.H.
AU - Kumararatne, Dinakantha
AU - Hauck, Fabian
AU - Allende, Luis M.
AU - Rodríguez-Gallego, Carlos
AU - Elfeky, Reem
AU - Rubin, Tamar
AU - Boztug, Kaan
AU - Fleisher, Thomas A.
AU - Rosenzweig, Sergio D.
N1 - Publisher Copyright:
© 2026 American Society of Hematology
PY - 2026/3/10
Y1 - 2026/3/10
N2 - The transcription factor IKAROS plays an important role in lymphocyte development, differentiation, and as a tumor suppressor. To date, >70 IKAROS germ line heterozygous variants have been reported in patients with primary immunodeficiency (PID)/inborn errors of immunity (IEI) and leukemia, and this number continues to grow. Germ line IKAROS loss- and gain-of-function mutations have been linked to immunodeficiency, immune dysregulation, and hematologic malignancies, with a broad spectrum of clinical manifestations. Routine next-generation sequencing approaches in patients with PID/IEI have facilitated the identification of IKAROS variants, including several cases with variants of uncertain significance (VUS). To determine the VUS’ functional behavior, we systematically generated constructs recapitulating those changes and tested IKAROS functions in vitro. We also conducted an in-depth examination of the C-terminal dimerization domain using alanine-scanning mutagenesis to identify amino acids critical for dimerization and other functions. This work provides a comprehensive description of the biologic impact of 81 previously unreported and/or untested IKAROS variants, including 33 patient-detected germ line VUS and 48 laboratory-generated mutations in the dimerization domain. Among them, 15 of the patient-detected variants, primarily mapping to IKAROS DNA-binding or dimerization domains, and at least 21 of the laboratory-generated mutations, impaired IKAROS function and could explain or result in human disease. VUS located in between IKAROS DNA binding and dimerization domains were less likely to be functionally deleterious. Of note, both positive and negative functional data herein generated can be relevant for patients carrying these IKAROS variants, helping to establish a diagnosis and guide treatment decisions.
AB - The transcription factor IKAROS plays an important role in lymphocyte development, differentiation, and as a tumor suppressor. To date, >70 IKAROS germ line heterozygous variants have been reported in patients with primary immunodeficiency (PID)/inborn errors of immunity (IEI) and leukemia, and this number continues to grow. Germ line IKAROS loss- and gain-of-function mutations have been linked to immunodeficiency, immune dysregulation, and hematologic malignancies, with a broad spectrum of clinical manifestations. Routine next-generation sequencing approaches in patients with PID/IEI have facilitated the identification of IKAROS variants, including several cases with variants of uncertain significance (VUS). To determine the VUS’ functional behavior, we systematically generated constructs recapitulating those changes and tested IKAROS functions in vitro. We also conducted an in-depth examination of the C-terminal dimerization domain using alanine-scanning mutagenesis to identify amino acids critical for dimerization and other functions. This work provides a comprehensive description of the biologic impact of 81 previously unreported and/or untested IKAROS variants, including 33 patient-detected germ line VUS and 48 laboratory-generated mutations in the dimerization domain. Among them, 15 of the patient-detected variants, primarily mapping to IKAROS DNA-binding or dimerization domains, and at least 21 of the laboratory-generated mutations, impaired IKAROS function and could explain or result in human disease. VUS located in between IKAROS DNA binding and dimerization domains were less likely to be functionally deleterious. Of note, both positive and negative functional data herein generated can be relevant for patients carrying these IKAROS variants, helping to establish a diagnosis and guide treatment decisions.
UR - https://www.scopus.com/pages/publications/105031456762
U2 - 10.1182/bloodadvances.2025017243
DO - 10.1182/bloodadvances.2025017243
M3 - Article
C2 - 41380100
AN - SCOPUS:105031456762
SN - 2473-9529
VL - 10
SP - 1522
EP - 1536
JO - Blood Advances
JF - Blood Advances
IS - 5
ER -